amitryptyline metabolism pathway
2C19 activates it
2D6 deactivates
2D6 genotypes
- non-functional = 3-8
amitryptyline 2C19 recommendations
- standard dose in extensive and intermediate
amitryptyline 2D6 recommendations
- 25% reduction in intermediate
simvastatin gene involved in metabolism
SLCO1B1
simvastatin genotypes/phenotypes
simvastatin dosing recommendations
methotrexate metabolism by
SLC19A1
methotrexate mutation
SNP at SLC19A1
methotrexate recommendations
no definitive recommendations
-higher risk of toxicity has been seen
clopidogrel metabolism
2C19
clopidogrel phenotypes
clopidogrel recommendations
any loss of function allele should get alternative therapy
-still use in ultra rapid
bupropion metabolised by
2B6
bupropion moderately inhibits
2D6
gene related to smoking cessation in bupropion
ANKK1
bupropion recommendations
- ANKK1 AA or AG may have decreased response
codeine metabolism
2D6
codeine recommendations
-alternative in ultra rapid and poor
aripiprazole metabolism
3A4
2D6
aripiprazole recommendations
- poor 2D6 + 3A4 inhib = reduce to 1/4
drugs to do HLA-B*5701 test for
abacavir
carbamazepine
patients to do HLA testing when using allopurinol
chinese
warfarin metabolism
VKORC
2C9